



Published: 07:00 CEST 24-08-2018 /GlobeNewswire /Source: Kiadis Pharma N. V. / : KDS /ISIN: NL0011323407

Kiadis Pharma to announce Financial Results for the six months ended June 30, 2018

Kiadis Pharma to announce Financial Results for the six months ended June 30, 2018

Amsterdam, The Netherlands, August 24, 2018 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing a T-cell immunotherapy product candidate designed to reduce Graft versus Host Disease (GVHD) and relapse after hematopoietic stem cell transplantations (HSCT), will be announcing Financial Results for the six months ended June 30, 2018 at 7:00am CEST on Friday, August 31, 2018.

For more information, please contact:

Kiadis Pharma:

Karl Hård, Head of IR & Communications
Tel. +31 611 096 298
k.hard@kiadis.com

Optimum Strategic Communications:

Mary Clark, Supriya Mathur, Hollie Vile
Tel: +44 203 714 1787
kiadis@optimumcomms.com